HR and invasive breast carcinoma: According to IHC analyses of 11 invasive breast cancer specimens, excluding 1 tumor that was not assessed by IHC (Case 1), 40% (4 out of 10) of tumors were HR − /HER2 + , whereas the remaining 60% were the HR + /HER2- subtype.